CURRENT CLINICAL INTERESTS
Patients with acute leukemias and myelodysplastic syndromes
CURRENT RESEARCH INTERESTS
1. New designs for clinical trials particularly in AML
2. Relation between response and survival in hematologic
malignancies
RESEARCH DESCRIPTION
1. New designs for clinical trials - patients
and physician are poorly served by the current phase 1-phase 2-phase 3
paradigm. Bayesian methodology, while not problem-free, permits more
flexible and adaptive designs. These include designs that (a)
simultaneously monitor multiple endpoints (such as response and
toxicity, or CR and survival), and (b) permit randomization
probabilities to shift to reflect current data.
2. Response and survival - new criteria for
response to therapy for AML have been promulgated. These include “CRp”,
“CRi”, “hematologic improvement”, and “marrow CR”.
However, while these responses indicate that a treatment is
“active”, their effect on survival, the outcome of most interest
to patients, is unknown. To examine this multivariate analyses are
used, in which type of response is considered along with other
covariates known to effect survival, such as age and cytogenetics.
SELECTED
PUBLICATIONS
Estey E, Thall PF: New designs for phase II clinical trials. Blood
102:442-448, 2003.
Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl
S, Thomas DA, Ferrajoli A, O’Brien S, Wathen JK, Xiao L-C, Berry DA,
Estey EH. Adaptive randomized study of Idarubicin and
Cytarabine versus Troxacitabine and Cytarabine versus Troxacitabine
and Idarubicin in untreated patients 50 years or older with adverse
karyotype acute myeloid leukemia. J. Clin. Oncol. 21:1722-1727, 2003.
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian
H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Blood 107:3469-3473, 2006.
Estey E, Dohner H. Acute myeloid leukemia.
Lancet 368:1894-1907, 2006.
Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR,
Estey EH. The clinical spectrum of adult acute myeloid leukemia associated with core binding factor translocations.
Br. J. Haematol.
135:165-173, 2006.
Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients.
J. Clin. Oncol.
25:1908-1915, 2007.
Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced intensity conditioning (RIC) regimens for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood
109:1395-1400, 2007
Estey E. "Fairest of them
all" for myelodysplastic syndromes. Blood 111:6, 2008.
Thall
P, Nguyen H, Estey E.
Patient-specific dose finding based on bivariate outcomes and
covariates. Biometrics 64:1126-36,
2008.
Epub 3/19
Gardner A, Mattiuzzi G,
Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.
Randomized comparison of “neutropenic” and non-neutropenic
diet in patientsu Undergoing remission
induction therapy for acute myeloid leukemia . J. Clin. Oncol. 26:5684-5688,
2008.
Sekeres M, Elson P,
Kalaycio, Advani A, Copelan E, Faderl S, Kantarjian H, Estey
E. Time from diagnosis to treatment initiation
predicts survival in younger, but not older, acute myeloid leukemia
patients. Blood 113:28-36, 2009.
|
